258 related articles for article (PubMed ID: 1423326)
1. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
Melief CJ; Kast WM
Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
[TBL] [Abstract][Full Text] [Related]
2. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.
Melief CJ; Kast WM
Ciba Found Symp; 1994; 187():97-104; discussion 104-12. PubMed ID: 7796678
[TBL] [Abstract][Full Text] [Related]
3. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses.
De Bruijn ML; Nieland JD; Schumacher TN; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1992 Nov; 22(11):3013-20. PubMed ID: 1425925
[TBL] [Abstract][Full Text] [Related]
5. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
6. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis.
Purtha WE; Myers N; Mitaksov V; Sitati E; Connolly J; Fremont DH; Hansen TH; Diamond MS
Eur J Immunol; 2007 Jul; 37(7):1845-54. PubMed ID: 17559174
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
Melief CJ; Kast WM
Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
[TBL] [Abstract][Full Text] [Related]
10. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
11. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells.
Macatonia SE; Patterson S; Knight SC
Immunology; 1991 Nov; 74(3):399-406. PubMed ID: 1769689
[TBL] [Abstract][Full Text] [Related]
12. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
13. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
14. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
15. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
16. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes.
Sijts AJ; Ossendorp F; Mengedé EA; van den Elsen PJ; Melief CJ
J Immunol; 1994 Jan; 152(1):106-16. PubMed ID: 8254184
[TBL] [Abstract][Full Text] [Related]
17. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
Lu J; Celis E
Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
[TBL] [Abstract][Full Text] [Related]
18. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
20. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
Lipford GB; Bauer S; Wagner H; Heeg K
Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
